Cargando…

Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis

Oxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Jun, Kotani, Kazuhiko, Gugliucci, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750165/
https://www.ncbi.nlm.nih.gov/pubmed/34942993
http://dx.doi.org/10.3390/antiox10121891
_version_ 1784631399187218432
author Watanabe, Jun
Kotani, Kazuhiko
Gugliucci, Alejandro
author_facet Watanabe, Jun
Kotani, Kazuhiko
Gugliucci, Alejandro
author_sort Watanabe, Jun
collection PubMed
description Oxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on this issue, we performed a meta-analysis of data on PON1 activity in COPD. Electronic databases (MEDLINE, Embase and CENTRAL) were searched for available studies on PON1 activity in patients with stable COPD published before October 2021. A meta-analysis was performed using random-effects models. Twelve studies (12 studies on paraoxonase and three on arylesterase) were identified. Patients with COPD had lower levels of paraoxonase activity (standard mean difference [SMD] −0.77, 95% confidence interval [CI] −1.35 to −0.18) and arylesterase activity (SMD −1.15, 95% CI −1.95 to −0.36) in comparison to healthy controls. In subgroup analyses, paraoxonase activity was lower in patients of studies as consisted of mainly non-severe COPD (SMD −1.42, 95% CI −2.04 to −0.79) and, by contrast, slightly higher in patients of studies including severe COPD (SMD 0.33, 95% CI 0.02 to 0.64) in comparison to healthy controls. Arylesterase activity showed a similar trend. Overall, PON1 activity was lower in patients with COPD, suggesting that PON1-related antioxidant defense is impaired in COPD. Future studies are warranted.
format Online
Article
Text
id pubmed-8750165
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87501652022-01-12 Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis Watanabe, Jun Kotani, Kazuhiko Gugliucci, Alejandro Antioxidants (Basel) Systematic Review Oxidative stress is a driving factor in the pathophysiology of chronic obstructive pulmonary disease (COPD). While paraoxonase 1 (PON1) is an antioxidant enzyme and a potential biomarker of this disease, data regarding the status of PON-1 in COPD are inconclusive. In this regard, to shed light on this issue, we performed a meta-analysis of data on PON1 activity in COPD. Electronic databases (MEDLINE, Embase and CENTRAL) were searched for available studies on PON1 activity in patients with stable COPD published before October 2021. A meta-analysis was performed using random-effects models. Twelve studies (12 studies on paraoxonase and three on arylesterase) were identified. Patients with COPD had lower levels of paraoxonase activity (standard mean difference [SMD] −0.77, 95% confidence interval [CI] −1.35 to −0.18) and arylesterase activity (SMD −1.15, 95% CI −1.95 to −0.36) in comparison to healthy controls. In subgroup analyses, paraoxonase activity was lower in patients of studies as consisted of mainly non-severe COPD (SMD −1.42, 95% CI −2.04 to −0.79) and, by contrast, slightly higher in patients of studies including severe COPD (SMD 0.33, 95% CI 0.02 to 0.64) in comparison to healthy controls. Arylesterase activity showed a similar trend. Overall, PON1 activity was lower in patients with COPD, suggesting that PON1-related antioxidant defense is impaired in COPD. Future studies are warranted. MDPI 2021-11-26 /pmc/articles/PMC8750165/ /pubmed/34942993 http://dx.doi.org/10.3390/antiox10121891 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Watanabe, Jun
Kotani, Kazuhiko
Gugliucci, Alejandro
Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis
title Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis
title_full Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis
title_fullStr Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis
title_full_unstemmed Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis
title_short Paraoxonase 1 and Chronic Obstructive Pulmonary Disease: A Meta-Analysis
title_sort paraoxonase 1 and chronic obstructive pulmonary disease: a meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750165/
https://www.ncbi.nlm.nih.gov/pubmed/34942993
http://dx.doi.org/10.3390/antiox10121891
work_keys_str_mv AT watanabejun paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis
AT kotanikazuhiko paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis
AT gugliuccialejandro paraoxonase1andchronicobstructivepulmonarydiseaseametaanalysis